Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib in R/R MDS and AML (BERGAMO)
NCT03824080Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of bemcentinib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by GWT-TUD. Started Dec 2018; status: completed.
02
Drugs
bemcentinib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03824080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824080.